High serum galectin-3 has been associated with heart failure incidence and adverse outcomes [14, 15]; hence, the 2017 ACC/AHA/HFSA (American College of Cardiology/American Heart Association/Heart Failure Society of America) have incorporated the biomarker as a possibly useful tool for risk stratification of chronic heart failure patients [16]. The gene discussed is LGALS3; the disease is heart failure.